Sarah Cannon Research Institute shared a post on LinkedIn:
“We are honored to celebrate the extraordinary career of Dr. Howard “Skip” Burris, who will retire as President and Chief Medical Officer of Sarah Cannon Research Institute at the end of this year.
We are pleased that his guidance will continue in an advisory capacity, where he will support our relationships with biopharma partners and help steer key initiatives related to Accelero.
Dr. Burris’s visionary leadership has shaped the future of cancer research – from founding the first community-based phase I program to initiating more than 850 first-in-human trials that led to FDA-approved therapies.
As we thank Dr. Burris for his decades of service, we also welcome a new chapter of leadership:
- David R. Spigel, MD, incoming President and CMO
- Melissa Johnson, incoming Chief Scientific Officer
- Erika Hamilton, MD, FASCO, incoming Chief Development Officer, Late-Phase
- Vivek Subbiah, MD, continuing as Chief, Early-Phase Drug Development
These leaders will carry forward our mission to advance cancer care through innovation, collaboration, and scientific excellence.
Read the full announcement.”
Proceed to the video attached to the post.
More posts featuring Sarah Cannon Research Institute.
